Helena Biosciences announce the launch of Glyco Liver Profile
Press release
Helena announce the launch of Glyco Liver Profile
Ghent, Belgium
Friday 4th October
Helena Biosciences are pleased to announce the launch of the Glyco Liver Profile at the world’s first Liver Glycomics Congress which saw hundreds of scientists and commercial specialists from Belgium, the UK and many other countries convene in the beautiful city of Ghent, Belgium this week to understand this revolutionary new technology jointly developed by VIB-Ghent University and Helena Biosciences.
Over the course of two days, the event covered 30 presentations on liver disease diagnosis and prognosis — providing context and understanding on many of the innovations and challenges taking place in healthcare today. Professor Claudio Tiribelli from the Italian Liver Foundation opened with a headline lecture, followed by many world-class speakers addressing the wide variety of issues and clinical practices affecting hospital professionals and researchers daily.
The Glyco Liver Profile itself is a major new diagnostic product that will shortly be on the front-line of diagnostic medicine and an essential part of how we diagnose, monitor and predict liver disease.
Dr Adam Stephenson, Director of Helena Biosciences commented, “Helena Biosciences have been working extremely hard in collaboration with VIB and Ghent University to deliver the world’s first glycomics product to market, and this exciting event gathers many of the world’s leading experts in hepatology from around the world. We’re excited to demonstrate the Glyco Liver Profile to such an esteemed audience and can’t wait to see it in routine use around the world.”
This launch has been a long time in the making. Starting out as a PhD research project, the inventor of the technology Nico Callewaert of VIB and Ghent University worked in collaboration with Hans Van Vlierberghe of UZ Gent, with the generous support of the Foundation Fournier-Majoie, to prove the link between N-glycan analysis and liver fibrosis. The technology rapidly evolved as a proven prognostic tool with the potential to monitor inflammation levels — making this a potential biomarker with incredible reach and power for clinical monitoring and prediction.
As Nico Callewaert recalls, “we started to see this as a major technology that could be used in clinical practice and that one needed commercial reach through a commercial partner. We found Helena Biosciences and the rest is history.”
Beyond hosting the first Liver Glycomics Congress, Helena Biosciences have a full year’s programme of demonstrations, meetings and exhibitions — including a presence at the prestigious International Liver Congress being held in London next April.
To find out more, visit www.liver-glyco-profile.co.uk
Document info:
HN0051
4 October 2019 15:21
Contact details
Our Marketing department can help with your questions:
Email marketing@helena-biosciences.com
Telephone +44 (0)191 482 8440
About Helena Biosciences 
